ACXP 241115 3.00C (ACXP241115C3000) Stock Options, News & Quotes

0.02
-0.08-80.00%

15min DelayClose Nov 15 16:00 ET

0.05High0.02Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Stock_Drift

Sep 26 06:15

$Acurx Pharmaceuticals (ACXP.US)$

Jaguar8

Sep 26 06:13

NEWS

$Acurx Pharmaceuticals (ACXP.US)$
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
Acurx Pharmaceuticals (NASDAQ: ACXP)announced new analyses extending data on ibezapolstat's beneficial effects on the gut microbiome for C. difficile Infection (CDI) treatment. The data showed increased beneficial bacteria, reversing dysbiosis and contributing to CDI anti-recurrence. Ibezapolstat's favorable pharmacokinetics were c...

Trytosaveabit

Sep 26 06:05

Update

$Acurx Pharmaceuticals (ACXP.US)$ Reuters· 3 mins ago
Acurx Announces Additional Ibezapolstat Ph2B Results in Cdi as Well as Anthrax (B. Anthracis) Susceptibility to Acx-375 Analogues

Jaguar8

Sep 24 06:49

NEWS

$Acurx Pharmaceuticals (ACXP.US)$
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
Acurx Pharmaceuticals (NASDAQ: ACXP) announced results from its research on ibezapolstat in collaboration with Leiden University Medical Center (LUMC) at the International C. difficile Symposium. The research revealed high-resolution details of ibezapolstat's interaction with its mole...

Trytosaveabit

Aug 12 05:48

Possible upcoming catalysts

$Acurx Pharmaceuticals (ACXP.US)$ Along with the FDA answer coming on phase 3! (((((. ·Throughout the rest of this year, they will continue to roll out our Phase 2 results in either oral presentations or scientific posters (in some cases both), which will include results from new analyses as data become available, at various prominent scientific conferences including:
oIn September 2024, the World Antimicrobial Resistance conference in Philadelphia;oIn September 2024,...